Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
Funding to grow the insurance and digital therapeutics vertical in India
TRIS AMINO HCl is widely used as a diagnostic reagent and as a downstream processing buffer in the purification of commercial biopharmaceuticals
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
Key takeaways of Q3FY22 quarter & conference call highlights
Subscribe To Our Newsletter & Stay Updated
